Borrowings	3 Months Ended
Mar. 31, 2014
DebtDisclosureAbstract
Borrowings Disclosure	14. Borrowings Term Loan Agreement In connection with its acquisition of ViroPharma on November 11, 2013 Shire entered into a $2,600 million Facilities Agreement with, among others, Morgan Stanley Bank International Limited (acting as lead arranger and agent) (the “Facilities Agreement”). The Facilities Agreement was subsequently reduced to $1,200 million. At March 31, 2014 the Facilities Agreement comprises two credit facilities: (i) a $550 million term loan facility which matures on November 10, 2014, of which $350 million was utilized, and (ii) an $850 million term loan facility which matures on November 11, 2015, which was fully utilized. The $550 million term loan facility was further reduced in April 2014 to $350 million. Revolving Credit Facility (“RCF”) On November 23, 2010 the Company entered into a committed multicurrency revolving and swingline facilities agreement with a number of financial institutions, for which Abbey National Treasury Services Plc (trading as Santander Global Banking and Markets), Bank of America Securities Limited, Barclays Capital, Citigroup Global Markets Limited, Lloyds TSB Bank plc and The Royal Bank of Scotland plc acted as mandated lead arrangers and bookrunners. The RCF, which is for an aggregate amount of $1,200 million and includes a $250 million swingline facility, may be used for general corporate purposes and matures on November 23, 2015. As at March 31, 2014 Shire has drawn loans totalling $320 million under the RCF.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details